Tibet Aim Pharm

Tibet Aim Pharm FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Tibet Aim Pharm (002826.SZ) as of Nov 19, 2026 is 124.46 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 216.27 % — a change of -42.45% (lower).

FCF Conversion

124.46 %

YoY

-42.45%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Tibet Aim Pharm is 2025 124.46 % . FCF Conversion Rate (FCF/EBITDA) of Tibet Aim Pharm was 2024 216.27 % . It decreases by -42.45% lower compared to the previous year.

The Tibet Aim Pharm FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-215.41 CNY
Jan 1, 2019
-298.02 CNY
Jan 1, 2020
154.06 CNY
Jan 1, 2021
198.53 CNY
Jan 1, 2022
147.85 CNY
Jan 1, 2023
1,063.92 CNY
Jan 1, 2024
216.27 CNY
Jan 1, 2025
124.46 CNY
The Tibet Aim Pharm FCF Conversion history
YEARFCF ConversionYoY
124.46 %-42.45%
216.27 %-79.67%
1,063.92 %+619.58%
147.85 %-25.53%
198.53 %+28.86%
154.06 %-151.70%
-298.02 %+38.35%
-215.41 %-4,974.82%
4.42 %-93.67%
69.83 %-147.30%
-147.64 %+11.31%
-132.64 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tibet Aim Pharm Stock analysis

What does Tibet Aim Pharm do? Tibet Aim Pharm., Inc. generates revenue through the research, development, production, and sale of chemical drugs and Chinese medicines. The company's self-manufacturing medicine portfolio features miglitol tablets, hongjinxiaojie tablet, aceclofenac enteric-coated tablets, montmorillonite powder, and domperidone tablets. Third-party medicine offerings include gualoupi injection, nalmefene hydrochloride injection, oral liquid for children, cefotaxime sodium for injection, and carbetocin injection. Domestic and overseas markets are the primary sales channels for these products, with the company distributing its medicines across both segments. The firm's self-manufacturing medicines are sold to domestic healthcare providers and consumers, while third-party medicine products are distributed through partnerships with other pharmaceutical entities. The company's product mix caters to various therapeutic areas, including gastrointestinal, cardiovascular, and pediatric treatments. Revenue streams are derived from direct sales of its proprietary drugs and third-party agreements for distribution. Tibet Aim Pharm., Inc. serves the domestic Chinese market and international markets with its chemical drugs and Chinese medicines. The company's product range targets healthcare institutions, pharmacies, and end consumers for self-manufacturing medicines, while third-party medicine products are supplied to distributors and healthcare facilities. The business model relies on manufacturing and distributing a diverse portfolio of pharmaceutical products to meet market demand. Tibet Aim Pharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tibet Aim Pharm stock

FCF Conversion Rate (FCF/EBITDA) of Tibet Aim Pharm is 124.46 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Tibet Aim Pharm changed from 216.27 % to 124.46 %, representing a -42.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Tibet Aim Pharm since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Tibet Aim Pharm with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Tibet Aim Pharm

All Key Metrics — Tibet Aim Pharm